Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 23.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 240,915 shares of the company's stock after selling 72,322 shares during the quarter. Prudential Financial Inc. owned approximately 0.11% of Hims & Hers Health worth $5,825,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in HIMS. SlateStone Wealth LLC boosted its stake in Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after purchasing an additional 413 shares during the last quarter. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares in the last quarter. Harbour Investments Inc. boosted its position in Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock worth $127,000 after acquiring an additional 833 shares during the last quarter. Stonekeep Investments LLC grew its stake in Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock valued at $410,000 after acquiring an additional 882 shares in the last quarter. Finally, LPL Financial LLC grew its stake in Hims & Hers Health by 1.0% during the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company's stock valued at $2,369,000 after acquiring an additional 980 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 3,236 shares of the stock in a transaction on Monday, March 31st. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72. Following the completion of the transaction, the insider now directly owns 170,285 shares in the company, valued at $4,728,814.45. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,064,954 shares of company stock worth $37,984,259. Company insiders own 17.71% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HIMS shares. Leerink Partners boosted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Piper Sandler lifted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 25th. Citigroup reissued a "sell" rating and issued a $27.00 price objective on shares of Hims & Hers Health in a report on Thursday, March 6th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $37.31.

Hims & Hers Health Stock Down 7.4 %

NYSE:HIMS traded down $2.06 on Friday, reaching $25.93. 27,621,633 shares of the company's stock were exchanged, compared to its average volume of 14,689,114. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of 58.93 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The business has a fifty day moving average of $39.82 and a 200-day moving average of $29.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.